Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021GlobeNewsWire • 12/27/21
Predictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/22/21
Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business DevelopmentGlobeNewsWire • 12/07/21
Predictive Oncology Inc. (POAI) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/11/21
Predictive Oncology Inc. (POAI) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/08/21
Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research AdvancementsGlobeNewsWire • 10/19/21
Predictive Oncology Announces Results of Charter Amendment Proposal at Special MeetingGlobeNewsWire • 08/18/21
Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business UpdateGlobeNewsWire • 08/11/21
Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomesGlobeNewsWire • 08/03/21
Predictive Oncology Inc.'s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labsGlobeNewsWire • 06/22/21
Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 06/18/21
Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewsWire • 06/14/21